Document is current

Article History

Received: 14 November 2020

Accepted: 16 July 2021

First Online: 3 August 2021

Declarations

:

: This trial has received ethics approval from London - Surrey Research Ethics Committee on the 12th of July 2019, REC reference: 19/LO/0750. IRAS (UK Ethics) number: 258725 (Additional file ). Consent is covered above.

: Not applicable.

: CN has received speaker fees from Ferring, AbbVie, Takeda and Tillotts.Jonathan Syred: none.Sally Kerry: noneMicol Artom: noneLouise Sweeney: noneAilsa Hart has served as consultant, advisory board member or speaker for AbbVie, Atlantic, Bristol-Myers Squibb, Celltrion, Falk, Ferring, Janssen, MSD, Napp Pharmaceuticals, Pfizer, Pharmacosmos, Shire and Takeda. She also serves on the Global Steering Committee for Genentech.WCD has received speaker fees from Dr Falk Pharma,Stephanie Taylor: noneBorislava Mihaylova: noneChris Roukas: noneQA is a member of an advisory board for Allergan, Grunenthal and Pantheryx. Conference support/sponsorship from Allergan, Grunenthal and Alimentary Health. Site for a phase III study with Allergan.Laura Miller: noneRichard Pollok has served as consultant, advisory board member, speaker and/or received educational grants from Dr Falk, Pharmacosmos, Takeda, Janssen, Napp pharmaceuticals and Ferring pharmaceuticals.SS: noneImogen Stagg: noneHelen Terry: noneZZ: noneLD has received speaker fees from Janssen, AbbVie and Eli-Lilley, and consultancy fees from GL Assessments and Crohn’s & Colitis UKRona Moss-Morris received personal fees from training in CBT for irritable bowel syndrome (IBS) for Central and North West London NHS Foundation Trust and University of East Anglia, outside the submitted work. She receives payment for consultancy to Mahana Therapeutics and is one of the beneficiaries of a licence agreement with King’s College London and a private company for a web-based CBT product for IBS.